

From Promise to Progress

2023 Year End Report

The generous contributions the Muscular Dystrophy Association (MDA) receives from our community of partners, volunteers, donors, and staff are instrumental in empowering our families and propelling groundbreaking research for stronger futures. We are proud to be the #1 voluntary health organization for people living with neuromuscular disease. Reflecting on our achievements throughout 2023, we are thrilled to share some of the powerful advances made possible through your contributions.

We helped to bring 6 FDA-approved treatments to market this year, while launching the MDA Gene Therapy Support Network.

A Year of Breakthrough Drug Approvals

Your generous support helped to bring six groundbreaking FDA-approved therapies to market in 2023, including the first-ever gene therapy for [Duchenne muscular dystrophy](#), new treatments for [ALS](#), [Pompe](#), [myasthenia gravis](#), [Friedreich's ataxia](#), and others. To help families navigate the complexities of these novel treatments, we launched the MDA Gene Therapy Support Network, which provides assistance in locating resources and overcoming access barriers for people eligible for approved gene therapies.

[Learn More](#)



More Funding Grants Awarded to Advance Research

As leaders in the development of treatments for neuromuscular disease, MDA awarded over \$8.4 million to fund more than 37 new research grants, reinforcing our seven-decade commitment to neuromuscular research.

[Learn More](#)

Find an MDA Care Center Near You

MDA maintains the nation's largest network of multidisciplinary care clinics for people living with neuromuscular disease. This specialized disease-specific healthcare empowers families we serve to live stronger and love longer.

[Learn More](#)



Accelerating Innovation with MOVR

MOVR is the first neuroMuscular ObserVational Research data hub integrating clinical, genetic, and patient-reported data for various neuromuscular diseases, allowing us to connect people to clinical trials faster than before.

[Learn More](#)

MDA Summer Camp Enhances Lives

Our 2023 Summer Camps hosted 815 children and young adults, including 172 first-year participants, along with 570 volunteers that make camp a memorable experience for all who attend.

[Learn More](#)



MDA Advocates Fight for Accessible Air Travel

MDA advocates for access to healthcare, education, employment, travel, and more. In May, our viral [campaign](#) resulted in significant improvements for travelers with disabilities. Continue to advocate with us at [MDA.org/AirTravel](https://mda.org/AirTravel).

[Read More](#)



Registration Now Open for MDA Conference 2024

At MDA's 2023 Clinical & Scientific Conference, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research at the FDA, delivered the keynote speech to the global neuromuscular disease community. Don't miss the world's largest meeting on neuromuscular disease research in care in 2024.

[Register Here](#)